Alogliptin
Links shared publicly online about this topic
Alogliptin delayed at least two years
theheart.org — “The makers of alogliptin say it will be two years before they have the cardiovascular data needed by the FDA, while the EASD raises concerns over a possible cancer risk with insulin glargine.” View full resource at theheart.org
Most Recently Shared on June 30, 2009 at 8:05 pm By:
heartwire: Alogliptin delayed; cancer concerns with insulin glargine http://bit.ly/3SgOg4
Insufficient CV safety data for alogliptin, FDA says
theheart.org — “According to new guidance issued in December, the manufacturer will need to obtain more CV-safety data for the FDA, despite submitting its NDA back in 2007.” View full resource at theheart.org
Most Recently Shared on March 12, 2009 at 4:11 pm By:
"Insufficient" data: FDA applies tough new CV-safety requirements to diabetes drug alogliptin http://tinyurl.com/djbzot
FDA Issues Complete Response Letter to NDA for Alogliptin/Pioglitazone - MPR
empr.com — “Takeda announced that it received a complete response letter from the FDA regarding its New Drug Applications (NDAs) for alogliptin and fixed-dose combination alogliptin and pioglitazone for the treatment of type 2 diabetes.” View full resource at empr.com
Most Recently Shared on April 26, 2012 at 5:01 pm By:
FDA Issues Complete Response Letter to NDA for Alogliptin/Pioglitazone #diabetes #takeda http://t.co/KNCMpJxG
New Diabetes Drugs Alogliptin, Saxagliptin Show Promise in Studies
diabetes.webmd.com — “Two new drugs, alogliptin and saxagliptin, show promise at treating type 2 diabetes, researchers report.” View full resource at diabetes.webmd.com
Most Recently Shared on September 9, 2008 at 6:29 pm By:
WebMD Health News 2 New Drugs May Help Fight Diabetes: Two new drugs, alogliptin and .. http://tinyurl.com/5vlsqz
Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
prnewswire.com — “Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone.” View full resource at prnewswire.com
Most Recently Shared on July 26, 2011 at 12:56 pm By:
John Carroll Health Communicator
Two years after the FDA threw up a roadblock to Takeda's alogliptin, a diabetes drug, they're back with a new NDA. http://prn.to/nrjsFw
PPD Confirms Takeda Receives NDA Approval Of NESINA(R) (Alogliptin) From Japanese Ministry Of Health, Labour And Welfare
medicalnewstoday.com — “PPD, Inc. (Nasdaq: PPDI) confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 di” View full resource at medicalnewstoday.com
Most Recently Shared on April 28, 2010 at 1:11 pm By:
MNT Drug Approvals Health News
PPD Confirms Takeda Receives NDA Approval Of NESINA(R) (Alogliptin) From Japanese Ministry Of Health, Labour And Welfare http://mnt.to/3BPM
Family Medicine News & Articles - MDLinx - Diabetes Mellitus, Type 2; Pioglitazone; Alogliptin on #MDlinx
mdlinx.com — “Family Medicine News & Articles - MDLinx - Diabetes Mellitus, Type 2; Pioglitazone; Alogliptin on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on August 6, 2010 at 9:48 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatm... http://bit.ly/aWNNR5 #GM #mdlinx
Takeda Enrolls Clinical Trial Subject in Phase 3 Study of Alogliptin in China (February 9, 2011) | 2011 | Newsroom | Takeda Pharmaceutical Company Limited
takeda.com — “Osaka, Japan and Singapore, February 9, 2011 --- Takeda Pharmaceutical Company Ltd (TSE: 4502, --Takeda--) and its wholly-owned subsidiary, Takeda Global Research & Development Center Asia, (--TGRD Asia--) today announced the commencement of enrollment for alogliptin for the treatment of type 2 diabetes mellitus in the company--™s phase 3 clinical trial led out of China.” View full resource at takeda.com
Most Recently Shared on February 9, 2011 at 8:27 pm By:
Ooops URL - Takeda Enrolls Clinical Trial Subject in Phase 3 Study of Alogliptin in China (Takeda) http://bit.ly/hGWXvD
Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice - Zhang - Diabetes, Obesity and Metabolism - Wiley Online Library
onlinelibrary.wiley.com — “Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice - Zhang - Diabetes, Obesity and Metabolism - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on December 10, 2010 at 3:32 pm By:
Effects of chronic administration of alogliptin on the development of diabetes and βâ€*cell function in high fa... http://bit.ly/eLWASA
Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice - Zhang - Diabetes, Obesity and Metabolism - Wiley Online Library
onlinelibrary.wiley.com — “Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice - Zhang - Diabetes, Obesity and Metabolism - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on December 10, 2010 at 9:48 am By:
Effects of chronic administration of alogliptin on the development of diabetes and βâ€*cell function in high fa... http://bit.ly/eZpAI6
Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In Japan
medicalnewstoday.com — “Takeda Pharmaceutical Company Limited (Takeda) announced that an additional indication for NESINA® (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabet” View full resource at medicalnewstoday.com
Most Recently Shared on August 21, 2010 at 2:00 pm By:
Approval Of Additional Indication Of NESINA®: Combination Therapy With Thiazolidinediones For Type 2 Diabetes In J... http://mnt.to/3HHx
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan
medicalnewstoday.com — “Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for NESINA® (alogliptin), combination therapy w” View full resource at medicalnewstoday.com
Most Recently Shared on February 28, 2011 at 5:05 pm By:
Furiex Confirms Takeda Receives Approval Of Additional NESINA(R) Combination Therapies With Sulfonylurea And Biguanide... http://mnt.to/3RGd
Takeda heads back to FDA with diabetes blockbuster hopeful - FierceBiotech
fiercebiotech.com — “Two years after the FDA handed back Takeda's NDA for the diabetes drug alogliptin, the Japanese pharma company has come back and re-filed its application with interim cardiovascular safety data it Read more...” View full resource at fiercebiotech.com
Most Recently Shared on July 26, 2011 at 1:18 pm By:
RT @Celerant_Am: Takeda heads back to #FDA with #diabetes blockbuster hopeful http://t.co/NAv1DaD RT @FierceBiotech #bio2011
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
